[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350456-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350456-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mapping-intratumor-heterogeneity-across-layers-for-advancing-immunotherapy","Mapping intratumor heterogeneity across layers for advancing immunotherapy","","Intratumor heterogeneity (ITH) spans genetic, epigenetic, transcriptional, proteomic, and immunopeptidomic diversity and extends beyond DNA variation through nonmutational plasticity. Dynamic, distinct cancer cell states create changing immune visibility by altering antigen processing, presentation, and peptide abundance across clones and locations. A multidimensional view is summarized across cancer types, emphasizing how layered ITH constrains immunotherapy efficacy. Integrating measurements across layers is proposed to improve biomarker identification and enable more precise immune-based treatment strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mapping-intratumor-heterogeneity-across-layers-for-advancing-immunotherapy/350456/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mapping-intratumor-heterogeneity-across-layers-for-advancing-immunotherapy/350456.png","ImageObject",300,407,{"name":42,"@type":43},"Mimi","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does intratumor heterogeneity (ITH) include according to the document?","Question",{"text":63,"@type":64},"ITH encompasses genetic, epigenetic, transcriptional, proteomic, and immunopeptidomic diversity, and also includes nonmutational heterogeneity and plasticity that create dynamic cancer cell states.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does variation in antigen processing and peptide abundance affect immunotherapy?",{"text":68,"@type":64},"Differences across cancer clones and cell states yield spatially and temporally distinct immune niches, which shape immune recognition and can constrain therapeutic response.",{"name":70,"@type":61,"acceptedAnswer":71},"What approach is proposed to improve immunotherapy biomarker identification?",{"text":72,"@type":64},"The document proposes integrating measurements across multiple layers of ITH to improve biomarker identification and to inform more precise immune-based treatment strategies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350456,1790191044,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":97,"preview_urls":146},2336477974920,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Cell. Author manuscript; available in PMC 2026 June 21. |\n| --- | --- |\n\nPublished in final edited form as:  \nCell. 2026 April 16; 189(8): 2416–2440. doi:10.1016/j.cell.2026.03.025 .  \nMapping intratumor heterogeneity across layers for advancing immunotherapy  \nJean-Christophe Marine 1,2 , Osnat Bartok3 , Shira Sagie3,4 , Pietro Paolo Vitiello5,6 , Alberto Bardelli5,6 , Chen Weller3 , Tian-Gen Chang7 , Claudia Tonelli 1,2 , Stefani Spranger8,9,10 , Eytan Ruppin7,11 , Yardena Samuels3,*  \n1Laboratory for Molecular Cancer Biology, Center for Cancer Biology, VIB, Leuven, Belgium  \n2Laboratory for Molecular Cancer Biology, Department of Oncology, KULeuven, Leuven, Belgium  \n3 Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel  \n4Jusidman Cancer Center, Sheba Medical Center, 52621 Ramat Gan, Israel  \n5 Department of Oncology, Molecular Biotechnology Center, University of Torino, 10126 Turin, Italy  \n6 IFOM ETS, The AIRC Institute of Molecular Oncology, 20139 Milan, Italy  \n7Cancer Data Science Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA  \n8Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA  \n9 Department of Biology, MIT, Cambridge, MA, USA  \n10 Ragon Institute of Mass General Brigham, MIT, and Harvard, Cambridge, MA, USA  \n11Translational Research Institute, The Jim and Eleanor Randall Department of Surgery, CedarsSinai Medical Center, Los Angeles, CA, USA  \nSUMMARY  \nIntratumor heterogeneity (ITH) encompasses genetic, epigenetic, transcriptional, proteomic, and immunopeptidomic diversity. Beyond genetic heterogeneity, it is increasingly clear that nonmutational heterogeneity and plasticity generate dynamic cancer cell states with distinct immune visibility. These layers of complexity converge on the immunopeptidome, the repertoire of peptides displayed by major histocompatibility complex molecules through which tumor cells  \nThis is an open access article under the CC BY-NC license ([https://creativecommons.org/licenses/by-nc/4.0/](https://creativecommons.org/licenses/by-nc/4.0/)).  \n*[Correspondence: yardena.samuels@weizmann.ac.il](Correspondence: yardena.samuels@weizmann.ac.il).  \nDECLARATION OF INTERESTS  \nE.R. is a member of the scientific advisory board of GSK Oncology and Pangea Biomed. P.P.V. served in a consulting role for Biocartis and has received speaking fees from Biocartis and Merck outside of the current manuscript. A.B. served in a consulting/ advisory role for Guardant Health. A.B. received research support from NeoPhore, AstraZeneca, and Boehringer Ingelheim outside of the current manuscript. A.B. is a co-founder and shareholder of NeoPhore and a shareholder of Kither Biotech. A.B. is a member of the scientific advisory board of NeoPhore.  \nDECLARATION OF GENERATIVE AI AND AI-ASSISTED TECHNOLOGIES IN THE MANUSCRIPT PREPARATION PROCESS  \nDuring the preparation of this work, the authors used ChatGPT 5.2 to improve the clarity and for language editing. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the published article.  \nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript  \nMarine et al. Page 2  \nare surveyed by T cells. Variation in antigen processing, presentation, and peptide abundance across cancer clones and cell states yields spatially and temporally distinct immunological  \nniches that shape immune recognition and therapeutic response. Here, we summarize how multidimensional ITH manifests across cancer types and constrains immunotherapy efficacy.  \nWe propose that integrating measurements across layers is a promising direction for improving biomarker identification and informing more precise immune-based treatment strategies.  \nINTRATUMOR HETEROGENEITY: A MUL","cbCaisv4wZEqzzXz","https://ap.wps.com/l/cbCaisv4wZEqzzXz","pdf",2082713,47,"English","# Summary\n# Intratumor heterogeneity: A multidimensional problem\n## Non-mutational plasticity and dynamic tumor states\n## Links to immune recognition and therapy response\n# Proposed multidimensional integration for better biomarkers","[{\"question\":\"What does intratumor heterogeneity (ITH) include according to the document?\",\"answer\":\"ITH encompasses genetic, epigenetic, transcriptional, proteomic, and immunopeptidomic diversity, and also includes nonmutational heterogeneity and plasticity that create dynamic cancer cell states.\"},{\"question\":\"How does variation in antigen processing and peptide abundance affect immunotherapy?\",\"answer\":\"Differences across cancer clones and cell states yield spatially and temporally distinct immune niches, which shape immune recognition and can constrain therapeutic response.\"},{\"question\":\"What approach is proposed to improve immunotherapy biomarker identification?\",\"answer\":\"The document proposes integrating measurements across multiple layers of ITH to improve biomarker identification and to inform more precise immune-based treatment strategies.\"}]","Mapping intratumor heterogeneity across layers for advancing immunotherapy | PDF",1790089131,118,[147,151,155,159,163],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/222c25f82c606160007182a1b2281668.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/74f4df2370df672e8a8243405cde2c85.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db9792bd2f22a32569359fbd9213e467.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2833fedaae1ed8028f020adcd50e09c5.webp",980,1268,{"page_no":97,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b4a7cc09c89c9690a810406e6466b2b2.webp",979,1267]